CHR-3996

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 205771

CAS#: 1235859-13-8

Description: CHR-3996 is an orally bioavailable, second-generation hydroxamic acid-based inhibitor of histone deacetylase (HDAC) with potential antineoplastic activity. HDAC inhibitor CHR-3996 inhibits HDAC, resulting in an accumulation of highly acetylated histones, the induction of chromatin remodeling, and the selective transcription of tumor suppressor genes; these events may result in the inhibition of tumor cell division and the induction of tumor cell apoptosis. This agent may upregulate HSP70 and downregulate anti-apoptotic Bcl-2 proteins more substantially than some first-generation HDAC inhibitors. HDACs, upregulated in many tumor cell types, are a family of metalloenzymes responsible for the deacetylation of chromatin histone proteins.


Price and Availability

Size
Price

1g
Ask price
Size
Price

2g
Ask price
Size
Price

5g
Ask price

CHR-3996, is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 205771
Name: CHR-3996
CAS#: 1235859-13-8
Chemical Formula: C21H20FN5O2
Exact Mass: 393.1601
Molecular Weight: 393.4142
Elemental Analysis: C, 64.11; H, 5.12; F, 4.83; N, 17.80; O, 8.13


Synonym: CHR3996; CHR-3996; CHR 3996.

IUPAC/Chemical Name: 2-(6-(((6-fluoroquinolin-2-yl)methyl)amino)bicyclo[3.1.0]hexan-3-yl)-N-hydroxypyrimidine-5-carboxamide

InChi Key: YUARZLJFVKGLFC-UHFFFAOYSA-N

InChi Code: InChI=1S/C21H20FN5O2/c22-14-2-4-18-11(5-14)1-3-15(26-18)10-23-19-16-6-12(7-17(16)19)20-24-8-13(9-25-20)21(28)27-29/h1-5,8-9,12,16-17,19,23,29H,6-7,10H2,(H,27,28)

SMILES Code: O=C(C1=CN=C(C2CC3C(NCC4=NC5=CC=C(F)C=C5C=C4)C3C2)N=C1)NO


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


Additional Information

CHR-3996 is an optimised HDAC Inhibitor for Treatment of Cancers. Histone Deacetylases (HDACs) are a family of metalloenzymes that are able to Deacetylase Histones, leading to repression of gene expression. Inhibition of HDACs has been shown to impact multiple aspects of tumour progression. First generation HDAC inhibitors have demonstrated the clinical utility of this class, but in many cases lack optimal pharmaceutical characteristics. CHR-3996 is a potent, orally-active, pharmaceutically optimised class I HDAC selective inhibitor. CHR-3996 was entered into clinical development in 2008.  (source: http://www.chromatherapeutics.com/CHR-3996.htm).
 
 
 


References

1: Moffat D, Patel S, Day F, Belfield A, Donald A, Rowlands M, Wibawa J, Brotherton D, Stimson L, Clark V, Owen J, Bawden L, Box G, Bone E, Mortenson P, Hardcastle A, van Meurs S, Eccles S, Raynaud F, Aherne W. Discovery of 2-(6-{[(6-fluoroquinolin-2-yl)methyl]amino}bicyclo[3.1.0]hex-3-yl)-N-hydroxypyrim idine-5-carboxamide (CHR-3996), a class I selective orally active histone deacetylase inhibitor. J Med Chem. 2010 Dec 23;53(24):8663-78. Epub 2010 Nov 16.  PubMed PMID: 21080647.